Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1KD7U)

Drug Name
ABI-011 Drug Info
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
PubChem CID
9940805
TTD Drug ID
DM1KD7U

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiogenesis (AGG) TTB8Y9K NOUNIPROTAC Inhibitor [1]
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Modulator [3]
Hepatocyte growth factor (HGF) TT4V2JM HGF_HUMAN Inhibitor [1]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [3]
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 8.544 6.927 7.253 7.839
Hepatocyte growth factor (HGF) DTT HGF 5.784 3.307 4.868 1.926
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Lymphoma
ICD Disease Classification 2A80-2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 3.61E-01 0.15 0.47
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01163071) A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
3 Company report (Indena)